Which has stronger valuation and earnings, RNTX or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A

Is RNTX or GALT more profitable?

Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% Galectin Therapeutics N/A N/A -176.83%

Does the media favor RNTX or GALT?

In the previous week, Rein Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 1 mentions for Galectin Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Galectin Therapeutics' score of 0.67 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNTX or STRO more profitable?

Rein Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% Sutro Biopharma -395.25% N/A -88.12%

Does the media favor RNTX or STRO?

In the previous week, Sutro Biopharma had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 6 mentions for Sutro Biopharma and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Sutro Biopharma's score of 0.41 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BCYC or RNTX?

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Bicycle Therapeutics' score of 0.34 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rein Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RNTX or ACIU?

In the previous week, AC Immune had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for AC Immune and 2 mentions for Rein Therapeutics. AC Immune's average media sentiment score of 1.26 beat Rein Therapeutics' score of 1.20 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rein Therapeutics (RNTX) Competitors

$0.80 -0.05 (-6.03%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.79 -0.01 (-1.46%)

As of 10/2/2026 07:30 PM Eastern

Compare

RNTX vs. GALT, STRO, BCYC, ACIU, and MGNX

Should you buy Rein Therapeutics stock or one of its competitors? Rein Therapeutics's main competitors and comparable companies include Galectin Therapeutics (GALT), Sutro Biopharma (STRO), Bicycle Therapeutics (BCYC), AC Immune (ACIU), and MacroGenics (MGNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rein Therapeutics compare to Galectin Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Rein Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, Rein Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Rein Therapeutics and 1 mentions for Galectin Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Galectin Therapeutics' score of 0.67 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Galectin Therapeutics	N/A	N/A	-176.83%

Rein Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 649.34%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 182.05%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Rein Therapeutics is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Summary

Rein Therapeutics beats Galectin Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Rein Therapeutics compare to Sutro Biopharma?

Rein Therapeutics (NASDAQ:RNTX) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

In the previous week, Sutro Biopharma had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 6 mentions for Sutro Biopharma and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Sutro Biopharma's score of 0.41 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Rein Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 649.34%. Sutro Biopharma has a consensus target price of $49.50, suggesting a potential upside of 222.48%. Given Rein Therapeutics' higher probable upside, equities analysts plainly believe Rein Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rein Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Sutro Biopharma	-395.25%	N/A	-88.12%

Rein Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Sutro Biopharma	$102.48M	2.48	-$191.09M	-$11.97	N/A

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sutro Biopharma beats Rein Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.20 beat Bicycle Therapeutics' score of 0.34 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rein Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.25	-$218.96M	-$2.73	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Rein Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Rein Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Rein Therapeutics	N/A	N/A	-63.69%

Bicycle Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Bicycle Therapeutics presently has a consensus target price of $13.86, indicating a potential upside of 309.97%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 649.34%. Given Rein Therapeutics' higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Rein Therapeutics beats Bicycle Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to AC Immune?

Rein Therapeutics (NASDAQ:RNTX) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Rein Therapeutics has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
AC Immune	$4.31M	64.23	-$85.03M	-$0.54	N/A

Rein Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market.

Rein Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Rein Therapeutics' return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
AC Immune	-245.32%	-100.17%	-28.36%

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, AC Immune had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for AC Immune and 2 mentions for Rein Therapeutics. AC Immune's average media sentiment score of 1.26 beat Rein Therapeutics' score of 1.20 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rein Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 649.34%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 175.74%. Given Rein Therapeutics' higher probable upside, research analysts plainly believe Rein Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

AC Immune beats Rein Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rein Therapeutics compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Rein Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Rein Therapeutics' return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Rein Therapeutics	N/A	N/A	-63.69%

MacroGenics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

MacroGenics presently has a consensus price target of $6.33, indicating a potential upside of 76.91%. Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 649.34%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Rein Therapeutics had 2 more articles in the media than MacroGenics. MarketBeat recorded 2 mentions for Rein Therapeutics and 0 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.76 beat Rein Therapeutics' score of 1.20 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Very Positive
Rein Therapeutics	Positive

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rein Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.53	-$74.62M	-$0.22	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Rein Therapeutics beats MacroGenics on 8 of the 14 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$69.07M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-0.47	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	14.00	123.39	78.87	52.62
Price / Book	-0.75	16.63	10.93	6.31
Net Income	-$49.87M	-$22.71M	$3.51B	$362.16M
7 Day Performance	6.99%	-2.99%	-2.00%	-1.66%
1 Month Performance	-9.94%	-10.81%	-6.19%	-4.68%
1 Year Performance	-32.71%	19.19%	8.03%	1.57%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	2.837 of 5 stars	$0.80 -6.0%	$6.00 +649.3%	-32.7%	$69.07M	N/A	N/A	10	News Coverage Positive News
GALT Galectin Therapeutics	1.804 of 5 stars	$3.87 -0.8%	$11.00 +184.2%	-9.9%	$254.88M	N/A	N/A	9
STRO Sutro Biopharma	2.9991 of 5 stars	$15.44 -3.4%	$47.30 +206.3%	+69.0%	$254.75M	$102.48M	N/A	128	Analyst Forecast
BCYC Bicycle Therapeutics	2.7599 of 5 stars	$3.60 -2.3%	$13.86 +285.5%	-59.6%	$251.61M	$72.86M	N/A	288	News Coverage Gap Up
ACIU AC Immune	3.2657 of 5 stars	$2.46 -2.6%	$7.50 +205.5%	-31.8%	$249.85M	$4.31M	N/A	106	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. GALT, STRO, BCYC, ACIU, and MGNX

How does Rein Therapeutics compare to Galectin Therapeutics?

Summary

How does Rein Therapeutics compare to Sutro Biopharma?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Summary

How does Rein Therapeutics compare to AC Immune?

Summary

How does Rein Therapeutics compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. GALT, STRO, BCYC, ACIU, and MGNX

How does Rein Therapeutics compare to Galectin Therapeutics?

Which has more volatility & risk, RNTX or GALT?

Does the media favor RNTX or GALT?

Do institutionals and insiders hold more shares of RNTX or GALT?

Is RNTX or GALT more profitable?

Do analysts recommend RNTX or GALT?

Which has stronger valuation and earnings, RNTX or GALT?

Summary

How does Rein Therapeutics compare to Sutro Biopharma?

Does the media favor RNTX or STRO?

Which has more risk & volatility, RNTX or STRO?

Do analysts rate RNTX or STRO?

Is RNTX or STRO more profitable?

Which has higher earnings & valuation, RNTX or STRO?

Do insiders and institutionals hold more shares of RNTX or STRO?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Does the media refer more to BCYC or RNTX?

Do insiders and institutionals hold more shares of BCYC or RNTX?

Which has higher earnings and valuation, BCYC or RNTX?

Is BCYC or RNTX more profitable?

Which has more volatility & risk, BCYC or RNTX?

Do analysts prefer BCYC or RNTX?

Summary

How does Rein Therapeutics compare to AC Immune?

Which has higher valuation & earnings, RNTX or ACIU?

Which has more risk & volatility, RNTX or ACIU?

Is RNTX or ACIU more profitable?

Do institutionals and insiders believe in RNTX or ACIU?

Does the media favor RNTX or ACIU?

Do analysts prefer RNTX or ACIU?

Summary

How does Rein Therapeutics compare to MacroGenics?

Is MGNX or RNTX more profitable?

Which has more volatility & risk, MGNX or RNTX?

Do analysts recommend MGNX or RNTX?

Does the media refer more to MGNX or RNTX?

Do institutionals and insiders believe in MGNX or RNTX?

Which has preferable earnings & valuation, MGNX or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools